Genomic Testing and Data Updates for High Risk Early-Stage Breast Cancer Patients

2024 ASCO® Annual Meeting Insights Hub
E

ASCO® 2024 Insights: "Elucidating the Immune Active State of HR+/HER2- MammaPrint High 2 Early BC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Erin Cobain
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Erin Cobain
358 views
June 18, 2024
Comments 0
Login to view comments. Click here to Login
09:10

Brief Update on Genomic Assays for Early Stage Breast Cancer

Adam Brufsky

448 views
12:57

Unequal Outcomes: Disparities in Breast Cancer for Black Women

Tiffany Onger

132 views
12:08

Racial Disparities in Breast Cancer Screening and Diagnosis

UChicago Medicine

N. Chen

114 views
27:15

Management of Higher Risk eBC Including BRCAm, HER2- Subtypes

2024 ASCO® Annual Meeting Insights Hub

M. Dolezal

363 views
25:45

Identifying Breast Cancer Subtypes and Recurrence Risk: Multigene As…

Han-Byoel Lee

324 views
10:10

ESMO Breast 2024 Summary: "Breaking New Ground With CDK 4/6i - Case-…

Insights from ESMO Breast 2024 Annual Meeting

W. Janni

326 views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.2K views
04:04

Clinical Overview of IO Development in ER+/HER2- BC

Laurence Buisseret

115 views
14:40

Neoadjuvant Chemo-IO for HR+/HER2- BC

Erin Cobain

616 views
12:37

Young Women With HR+/HER2- Breast Cancer: Options for Risk Assessment

University of Colorado Cancer Center

V. Borges

428 views